Vertex Pharmaceuticals is being accused by a group of advocates and physicians of refusing to take several steps that would widen access to its pricey cystic fibrosis medicines in predominantly poor countries.
In a recent Zoom call, company executives were urged to drop patent claims and implement a global pricing model reflecting R&D and production costs, which could make the treatments more affordable. Instead, the Vertex team maintained the company will use a nascent donation program to address the concerns, according to people who attended the Oct. 12 session.
The outcome frustrated a coalition pushing the company to alter its stance toward countries where cash-strapped governments are unable to meet pricing demands. The advocates and physicians also complained that, while Vertex maintained its donation program is a workable solution, the executives refused to disclose details about the extent of the initiative and how many people are benefiting.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect